Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N, Decimoni TC, Dyer MTD, May JR, van de Wetering G, Petersohn S, Nickel K, Silva A, Muniz DQB, Casagrande D Oliveira AP. Dhanji N, et al. Among authors: van de wetering g. J Med Econ. 2023 Jan-Dec;26(1):1108-1121. doi: 10.1080/13696998.2023.2252716. J Med Econ. 2023. PMID: 37632452 Free article.
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Majer I, van de Wetering G, Polanyi Z, Krishna A, Gray E, Roy A. Majer I, et al. Among authors: van de wetering g. Appl Health Econ Health Policy. 2017 Feb;15(1):45-55. doi: 10.1007/s40258-016-0271-0. Appl Health Econ Health Policy. 2017. PMID: 27550239
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS. Chatterjee A, et al. Among authors: van de wetering g. J Manag Care Spec Pharm. 2021 Nov;27(11):1532-1544. doi: 10.18553/jmcp.2021.27.11.1532. J Manag Care Spec Pharm. 2021. PMID: 34714110 Free PMC article.
Time to incorporate time in cost-effectiveness analysis.
van de Wetering G, Woertman WH, Adang EM. van de Wetering G, et al. Eur J Health Econ. 2012 Jun;13(3):223-6. doi: 10.1007/s10198-011-0374-3. Eur J Health Econ. 2012. PMID: 22252307 Free PMC article.
17 results